» Articles » PMID: 33456563

CXCL12-mediated HOXB5 Overexpression Facilitates Colorectal Cancer Metastasis Through Transactivating CXCR4 and ITGB3

Overview
Journal Theranostics
Date 2021 Jan 18
PMID 33456563
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is the major reason for the high mortality of colorectal cancer (CRC). However, the molecular mechanism underlying CRC metastasis remains unclear. Here, we report a novel role of homeobox B5 (HOXB5), a member of the HOX family, in promoting CRC metastasis. The expression of HOXB5 and its target genes were examined by immunohistochemistry in human CRC. Chromatin immunoprecipitation and luciferase reporter assays were performed to measure the transcriptional regulation of target genes by HOXB5. The metastatic capacities of CRC cells were evaluated by lung and liver metastatic models. The elevated expression of HOXB5 was positively correlated with distant metastasis, higher AJCC stage, and poor prognosis in CRC patients. HOXB5 expression was an independent and significant risk factor for the recurrence and survival in CRC patients. Overexpression of HOXB5 promoted CRC metastasis by transactivating metastatic related genes, C-X-C motif chemokine receptor 4 (CXCR4) and integrin subunit beta 3 (ITGB3). C-X-C motif chemokine ligand 12 (CXCL12), which is the ligand of CXCR4, upregulated HOXB5 expression through the extracellular regulated protein kinase (ERK)/ETS proto-oncogene 1, transcription factor (ETS1) pathway. The knockdown of HOXB5 decreased CXCL12-enhanced CRC metastasis. Furthermore, AMD3100, a specific CXCR4 inhibitor, significantly suppressed HOXB5-mediated CRC metastasis. HOXB5 expression was positively correlated with CXCR4 and ITGB3 expression in human CRC tissues, and patients with positive co-expression of HOXB5/CXCR4, or HOXB5/ITGB3 exhibited the worst prognosis. Our study implicates HOXB5 as a prognostic biomarker in CRC, and defines a CXCL12-HOXB5-CXCR4 positive feedback loop that plays an important role in promoting CRC metastasis.

Citing Articles

Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.


TLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma.

Hu F, Hu C, He Y, Sun Y, Han C, Zhang X Biomedicines. 2025; 13(1).

PMID: 39857735 PMC: 11761590. DOI: 10.3390/biomedicines13010151.


Estimate the relationship between CXCR4-SDF-1 axis and inhibitory molecules (CTLA4 and PD-1) in patients with colon cancer.

Abdul-Huseen S, Alabassi H Narra J. 2025; 4(3):e992.

PMID: 39816054 PMC: 11731802. DOI: 10.52225/narra.v4i3.992.


Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis.

Lee R, Ellison V, Forbes D, Gao C, Katanov D, Kern A Cancers (Basel). 2025; 16(24.

PMID: 39766093 PMC: 11674518. DOI: 10.3390/cancers16244194.


CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways.

Kravtsova-Ivantsiv Y, Goldhirsh G, Ciechanover A Proc Natl Acad Sci U S A. 2024; 121(52):e2416909121.

PMID: 39689179 PMC: 11670100. DOI: 10.1073/pnas.2416909121.


References
1.
Zhu C, Kong Z, Wang B, Cheng W, Wu A, Meng X . ITGB3/CD61: a hub modulator and target in the tumor microenvironment. Am J Transl Res. 2020; 11(12):7195-7208. PMC: 6943458. View

2.
Kim J, Takeuchi H, Lam S, Turner R, Wang H, Kuo C . Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005; 23(12):2744-53. DOI: 10.1200/JCO.2005.07.078. View

3.
Chu C, Cha S, Lin W, Lu P, Tan C, Chang C . Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/interleukin-6 pathway. Carcinogenesis. 2008; 30(2):205-13. DOI: 10.1093/carcin/bgn228. View

4.
Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

5.
Parvani J, Gujrati M, Mack M, Schiemann W, Lu Z . Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015; 75(11):2316-2325. PMC: 4452414. DOI: 10.1158/0008-5472.CAN-14-3485. View